rais pt ebitda follow
capit market day focus core kidney trend growth
opportun capit deploy guidanc continu
see near term head wind view improv capit effici
encourag increas focu home therapi opportun think
experi provid reason out-year optim final
biz look pois growth view posit
scale provid favor maintain hold rate
solid guidanc improv capit effici encourag
addit reiter full year guidanc manag provid
expect compani expect
gener adjust ep in-lin consensu
estim ex-calcimimet manag expect rev/tx grow
reflect propos medicar statutori increas partial off-set
on-going pressur commerci rate mix compani
expect gener revenu adjust ep
 reflect new definit remov
develop capital-expenditure add back sale leaseback proce contribut
nci bridg revenu includ neg impact
calcimimet assum
 dialysi kidney growth increment
intern contribut compani expect oi margin
remain roughli flat strong epo cost manag
off-set on-going labor cost pressur importantli view guidanc
sizabl expect step capital-expenditure guidanc
vs encourag manag drive
sharper focu capit effici growth
recent execut order propos model incentiv increas
util home base dialysi treatment focu educ
patient provid necessari resourc facilit home option
remain high largest provid home dialysi today major
exist dialysi center alreadi offer home therapi option
view well posit help facilit greater home util
compani outlin sever industri challeng face provid includ
high rate return in-cent treatment averag pd patient last
year loss rate gener lack pd train
nephrologist help combat challeng invest
across number area includ telemedicin remot monitor patient
tr target
ebitda adjust nci equiti incom
health manag navig predict model capabl manag reiter
expect benefit mandatori model year declin
thereaft given cumul benefit lower home labor cost time think increas
adopt pd patient particularli associ earli ckd identif could creat
potenti tailwind time
medicar advantag integr opportun uptick percentag
patient esrd expect centuri cure act expect see
commensur increas payor interest integrated/risk-shar dialysi payment option
look better manag grow complex popul total medicar patient
enrol plan today view compani well posit increas penetr
importantli compani experienc integr care platform facilit partnership
across kidney care continuum includ hospit discharg plan predict analyt
modal manag etc addit medicar advantag contract rate attract
rel medicar ff could help provid off-set on-going pressur labor cost mix
etc time
intern busi shift toward growth follow segment initi investment/ramp
busi profit expect contribut margin continu
grow come year compani pursu top line margin expans scale
segment remain primari focu expect growth come organ expans
 filter manag pipelin potenti target includ abil improv care
sustain econom model potenti scale align exist manag team
remain upbeat growth potenti segment expect becom
meaning piec total busi time
 capit strategi solid free cash flow guidanc leverag ratio pro
forma pend note redempt upcom debt matur view
financi flexibl increas focu capit effici favor expect capit
deploy remain on-going focu tuck-in acquisit debt repay share buy
back manag also provid bridg guidanc
includ earn growth capital-expenditure
offset expect shift toward home therapi time also anticip
ramp capital-expenditure spend next year fewer tradit dialysi center open
home center ad lower invest capital-expenditure cost modestli tweak
estim adjust ep adjust ebitda
reflect put take guidanc maintain hold rate rais
price target
page
revenu
revenu
revenu
revenu
revenu
amort net tax
page
base denver co davita inc lead provid dialysi servic unit state
intern patient suffer chronic kidney failur end stage renal diseas esrd
recent sale davita medic group optum allow debt repay share
repurchas on-going capit deploy activ
continu like core dialysi busi acknowledg potenti opportun tie
integr care longer term view near term fundament mix enthusiasm
expect improv capit effici somewhat off-set industri pressur labor ballot
initi slow organ volum trend rate share hold
valuat risk
price target base trade adjust ebitda-nci discount industri
peer freseniu medic fm view appropri given less product geograph
diversif recent sluggish organ volum trend
risk rate price target upsid risk includ better expect reimburs
oper perform downsid risk includ wors expect reimburs pressur
slow organ trend
compani mention note
david macdonald herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express
specif recommend report
